Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, December 5, 2022

Global prevalence estimates of poststroke fatigue: A systematic review and meta-analysis

 Why the fuck was this research done? You're so fucking out-of-date you somehow missed all this earlier research?

 Hell we've known of post stroke fatigue for years. So solve the damn problem, instead of just telling us it exists.

At least half of all stroke survivors experience fatigue Known since March 2017

Or is it 70%? Known since March 2015

Or is it 40%? Known since September 2017

I'd fire everyone involved including the editors of the International Journal of Stroke for printing this.

Global prevalence estimates of poststroke fatigue: A systematic review and meta-analysis

Abstract

Background and purpose:

Poststroke fatigue (PSF) is a common complication after stroke. However, information on the global prevalence of PSF and how this varies geographically and by population is lacking. Our aim was to examine the global prevalence of PSF and identify sources of heterogeneity in the published literature.

Methods:

Four medical databases (PubMed, EMBASE, PsycINFO, and Cochrane Database of Systematic Reviews) were searched from their inception to 28 February 2022. The Joanna Briggs Institute Critical Appraisal Instrument for studies reporting prevalence data (JBI) was used to assess the risk of bias (ROB) of the included studies. The primary outcome was the prevalence of PSF determined using a random-effects model. Subgroup analysis and meta-regression models were used to define the source of heterogeneity.

Results:

In all, 66 studies with 11,697 patients were included in this meta-analysis. The overall quality of the included studies was medium. The global pooled prevalence of PSF in stroke survivors was 46.79% (95% confidence interval (CI), 43.41–50.18%). The prevalence estimates of PSF based on the Fatigue Severity Scale (FSS), Multidimensional Fatigue Inventory-20 (MFI-20), and Fatigue Assessment Scale (FAS) were 47.44% (95% CI, 43.20–51.67%), 51.69% (95% CI, 44.54–58.83%), and 36.13% (95% CI, 23.07–49.18%), respectively. Prevalence rates of PSF were higher in females (53.19%; 95% CI, 46.46–59.92%), in hemorrhagic stroke (57.54%; 95% CI, 40.55–74.53%), in those with a college degree or higher (53.18%; 95% CI, 42.82–63.54%), and in those with unmarried or divorced status (59.78%; 95% CI, 44.72–74.83%).

Conclusions:

The prevalence of PSF in stroke survivors is high, affecting almost half of all stroke sufferers. PSF rates were higher with female gender, being unmarried or divorced, having a higher educational level, and being hemorrhagic compared to ischemic stroke.

Trial registration:

PROSPERO (CRD42021269441).

Get full access to this article

View all access and purchase options for this article.


No comments:

Post a Comment